Abstract
Patients with sickle cell disease (SCD) experience initial and recurrent venous thromboembolism (VTE) more commonly and at a younger age than the general population, and it confers a higher mortality for patients with SCD. However, limited evidence is available to guide anticoagulant use for VTE treatment in this population. The primary objective of this study is to characterize the effectiveness and safety of direct oral anticoagulants (DOAC) and warfarin for VTE treatment among patients with SCD. This single-center retrospective study includes adult patients with SCD who were diagnosed with VTE. Data was obtained from review of electronic health records for the 6 months after VTE diagnosis. Among the 22 patients treated initially with a DOAC, 6 (27%) developed recurrent VTE, none experienced major bleeding, and 3 (14%) experienced clinically relevant non-major bleeding (CRNMB). Similarly, of 15 patients initially treated with warfarin, 3 (20%) developed a recurrent VTE, 1 (7%) experienced major bleeding, and 2 (13%) experienced CRNMB. Twelve patients received more than one oral anticoagulant during the study period, most commonly due to a recurrent VTE, concern for non-adherence, or subtherapeutic INR. Overall, the incidence of VTE recurrence and bleeding events were similar between groups, but occurred at a higher rate than those found in major clinical trials of anticoagulant agents. Prescribers should continue to individualize therapeutic decision-making regarding oral anticoagulant therapy for VTE treatment for individuals with SCD based on patient-specific factors and anticipated ability to adhere to the drug regimen or required monitoring.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs11239-018-1637-y/MediaObjects/11239_2018_1637_Fig1_HTML.gif)
References
Bell EJ, Lutsey PL, Basu S, Cushman M, Heckbert SR, Lloyd-Jones DM, Folsom AR (2016) Lifetime risk of venous thromboembolism in two cohort studies. Am J Med 129:339.e19. https://doi.org/10.1016/j.amjmed.2015.10.014
Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE (2006) Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 119:897.e7. https://doi.org/10.1016/j.amjmed.2006.08.015
Naik RP, Streiff MB, Haywood C Jr, Nelson JA, Lanzkron S (2013) Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med 126:443–449. https://doi.org/10.1016/j.amjmed.2012.12.016
Naik RP, Streiff MB, Lanzkron S (2013) Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 35:352–358. https://doi.org/10.1007/s11239-013-0895-y
Stone RH, Bress AP, Nutescu EA, Shapiro NL (2016) Upper-extremity deep-vein thrombosis: a retrospective cohort evaluation of thrombotic risk factors at a university teaching hospital antithrombosis clinic. Ann Pharmacother 50:637–644
Novelli EM, Huynh C, Gladwin MT, Moore CG, Ragni MV (2012) Pulmonary embolism in sickle cell disease: a case-control study. J Thromb Haemost 10:760–766. https://doi.org/10.1111/j1538-7836.2012.04697.x
Vichinsky EP, Neumayr LD, Earles AN et al (2000) Causes and outcomes of the acute chest syndrome in sickle cell disease: National Acute Chest Syndrome Study Group. N Engl J Med 342:1855–1865. https://doi.org/10.1056/NEJM200006223422502
Kearon C, Akl EA, Ornelas J et al (2016) Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest 149:315–352. https://doi.org/10.1016/j.chest.2015.11.026
Comerota AJ, Ramacciotti E (2016) A Comprehensive overview of direct oral anticoagulants for the management of venous thromboembolism. Am J Med Sci 352:92–106. https://doi.org/10.1016/j.amjms.2016.03.018
Sparkenbaugh E, Pawlinski R (2013) Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol 162:3–14. https://doi.org/10.1111/bjh.12336
Muntane-Relat J, Ourlin JC, Domergue J, Maurel P (1995) Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, CYP3A4 in human hepatocytes in primary culture. Hepatology 22:1143–1153
Sparkenbaugh EM, Chantrathammachart P, Mickelson J et al (2014) Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood 123:1747–1756. https://doi.org/10.1182/blood-2013-08-523936
Bhat S, Han J (2017) Outcomes of rivaroxaban use in patients with sickle cell disease. Ann Pharmacother 51:357–358. https://doi.org/10.1177/1060028016681129
Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808. https://doi.org/10.1056/NEJMoa1302507
Baursachs R, Berkowitz SD, Brenner B et al (2010) Oral rivaroxaban for the treatment of symptomatic venous thromboembolism. N Engl J Med 363:2499–2510. https://doi.org/10.1056/NEJMoa1007903
Buller HR, Prins MH, Lensin AW et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297. https://doi.org/10.1056/NEJMoa1113572
Novelli EM, Gladwin MT (2016) Crises in sickle cell disease. Chest 149:1082–1093. https://doi.org/10.1016/j.chest.2015.12.016
Rosendaal FR, Cannegieter SC, van der Meer FJ et al (1993) A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 69:236–239
Wolters HJ, ten Cate H, Thomas LL, Brandjes DP, van der Ende A, van der Heiden Y, Statius van Eps LW (1995) Low-intensity oral anticoagulation in sickle-cell disease reverses the prethrombotic state: promise for treatment. Br J Haematol 90:715–717
Chen SY, Wu N, Gulseth M, LaMori J, Bookhar BK, Boulanger L, Fields L, Schein J (2013) One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm 19:291–301. https://doi.org/10.18553/jmcp.2013.19.4.291
Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S (2016) Use of direct oral anticoagulants in obese patients: guidance for the SSC of the ISTH. J Thromb Haemost 14:1308–1313. https://doi.org/10.1111/jth.13323
Tran E, Duckett A, Fisher S, Bohm N (2017) Appropriateness of direct oral anticoagulant dosing for venous thromboembolism treatment. J Thromb Thrombolysis 43:505–513
Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA (2017) Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 69:2779–2790. https://doi.org/10.1016/j.jacc.2017.03.600
Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balkrishnan R (2011) Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 86:273–277. https://doi.org/10.1002/ajh.21968
Ritho J, Liu H, Hartzema AG, Lottenberg R (2011) Hydroxyurea use in patients with sickle cell disease in a Medicaid population. Am J Hematol 86:888–890. https://doi.org/10.1002/ajh.22134
Rouleau-Mailloux E, Shahabi P, Dumas S et al (2016) Impact of regular activity on weekly warfarin dose requirement. J Thromb Thrombolysis 41:328–335. https://doi.org/10.1007/s11239-015-1248-9
Ansell J, Hirsh J, Hylek E, at al (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133:160–198. https://doi.org/10.1378/chest.08-0670
Kelley D, Jones LT, Wu J, Bohm N (2017) Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease. J Thromb Thrombolysis 43:463–468. https://doi.org/10.1007/s11239-016-1463-z
Acknowledgements
The project described was supported by the National Institutes of Health (NIH) National Center for Advancing Translational Science (NCATS) through Grant Number UL1TR001450.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable standards.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Roberts, M.Z., Gaskill, G.E., Kanter-Washko, J. et al. Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. J Thromb Thrombolysis 45, 512–515 (2018). https://doi.org/10.1007/s11239-018-1637-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-018-1637-y